Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Compassionate Use of Omegaven for PNALD
NCT02010034Completed
- Sponsor
- Children's Medical Center Dallas
- Start
- Aug 2013
- Primary completion
- Feb 2019
- Modality
- Lipid-based Nanoparticles
- Countries
- 1
01
Overview
Open-label, single-arm trial of eicosapentaenoic acid + docosahexaenoic acid in Parenteral Nutrition Associated Liver Disease (PNALD), sponsored by Children's Medical Center Dallas. Primary endpoint: Bilirubin in mg/dL at 12 weeks. Started Aug 2013; status: completed.
02
Drugs
eicosapentaenoic acid + docosahexaenoic acid
03
Conditions
Parenteral Nutrition Associated Liver Disease (PNALD)
Beyond the preview
Go deeper on NCT02010034.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02010034.